

From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Fri, 6 Aug 2021 14:37:36 +0000
To: [Redacted by agreement] (NIH/NIAID) [E]
Cc: [Redacted by agreement] (NIH/NIAID) [E]
Subject: FW: Contract HHSN272201700035I/75N93020F00003
Attachments: Task C12 Task Order Award - UGA PE.pdf

FYI, I think you should be aware since you are the COR on the Parent contract. If there is an inquiry this is the Task Order for the beagle experiments. Reading this article it appears that this is more about Dr Fauci than the experiments with beagles. I did a FOI response to the White Coat Project a few months ago. They are an animal rights group that was fishing.

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Friday, August 6, 2021 10:04 AM
To: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] @niaid.nih.gov>; [Redacted by agreement] (NIH/NIAID) [E]
[Redacted by agreement] @mail.nih.gov>
Cc: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] @nih.gov>
Subject: Contract HHSN272201700035I/75N93020F00003

<https://dailycaller.com/2021/08/04/anthony-fauci-niaid-georgia-beagle-experiment/>

We may get a call from the top.

[Redacted by agreement]

Contracting Officer, MID Research Contracts Branch-A
Office of Acquisitions, DEA, NIAID, NIH, DHHS
5601 Fishers Lane
Rockville, Maryland 20852 [Redacted by agreement]
Phone: [Redacted by agreement]

**NATIONAL INSTITUTES OF HEALTH
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
TASK ORDER**

1. CONTRACT NO. HHSN272201700035I	2. TASK ORDER NO. 75N93020F00003	3. REQUISITION NO. 5824798	
4(A). TASK ORDER AWARD DATE See Block 13C	4(B). TASK ORDER EFFECTIVE DATE See Block 13(C)	4(C). TASK ORDER COMPLETION DATE January 15, 2022	
5(A). AWARD AUTHORITY <i>(Pursuant to FAR 16.505, 41 USC 253)</i> FAR 1.602-1; FAR 43.103(a)		5(B). TYPE OF ORDE [X] Cost Reimbursement [] Firm Fixed Price	
6. ISSUING OFFICE <i>(Address correspondence to)</i> National Institutes of Health, HHS National Institute of Allergy and Infectious Diseases DEA, Office of Acquisitions 5601 Fishers Lane Rockville, MD 20852-9821		7. ADMINISTRATIVE OFFICE <i>(if different from block No. 6):</i>	
8. CONTRACTOR <i>(Name, address and ZIP code)</i> University of Georgia Research Foundation, Inc. 310 East Campus RD Tucker Hall Room 409 Athens, GA 30602-1589		9. CONTRACTING OFFICER'S REPRESENTATIVE <i>(Name, office code, and telephone number)</i> See Award Terms	
10(A). ACCOUNTING AND APPROPRIATION DATA FY 20 CAN 8470036 \$424,455			
10(B). FUNDING THIS ACTION \$424,455		10(C). TASK ORDER VALUE \$424,455	
11. DESCRIPTION OF SERVICES <i>(Scope of Work):</i> PURPOSE: To issue Task C12 for "Lymphatic Filariasis Vaccine (LFguard) Efficacy Trial in Dogs"			
12(A). NAME & TITLE OF SIGNER <i>(Typed)</i> Redacted by agreement - Contract Manager		13(A). CONTRACTING OFFICER NAME <i>(Typed)</i> Redacted by agreement OA, DEA, NIAID, NIH	
12(B). Signature Personal Info	12(C). DATE 9/14/2020	13(B). Signature	13(C). DATE

The subject Task Order, 75N93020F00003 (Task C12) is issued in accordance with the terms and conditions of the NIAID Preclinical Models of Infectious Diseases IDIQ base contract HHSN272201700035I. In addition to the terms and conditions described herein, the terms and conditions of the base contract shall be considered to apply to this Task Order.

SECTION B – SERVICES AND COSTS

ARTICLE B.1. BRIEF DESCRIPTION OF SERVICES

In accordance with Attachment 1, Statement of Work, The Contractor shall evaluate Proprietary Info infection in dogs. The secondary purpose is to determine whether Proprietary Info dogs can Proprietary Info. The third objective is to Proprietary Info. Vaccine will be provided by a third party NIAID designee.

ARTICLE B.2. ESTIMATED COST

- a. The estimated cost of the Base Period of this Task Order is \$424,455.

ARTICLE B.3. ADVANCED UNDERSTANDINGS

1. Contract Number Designation

On all correspondence submitted under this task order, the Contractor agrees to clearly identify the contract number, task order number and task that appear on the face page of the contract as follows:

Contract Number: HHSN272201700035I

Task Order Number: 75N93020F00003

Task: C12

2. Invoices

On all invoices for payment submitted under this task order, the Contractor agrees to clearly identify the contract number, task order number and task that appear on the contract face page as follows:

Contract Number: HHSN272201700035I

Task Order Number: 75N93020F00003

Task: C12

3. Indirect Costs

In no event, shall the final amount reimbursable for fringe and facilities and administrative costs exceed the provisional or final ceilings established in the negotiated Indirect Rate Agreement.

4. Subcontract

To negotiate a cost-reimbursement type subcontract with Subcontractor Info

Subcontractor Info for an amount not to exceed the following:

Subcontractor Info	Total Estimated Cost
Base period	Estimated Costs

SECTION C – STATEMENT OF WORK

ARTICLE C.1. STATEMENT OF WORK AND TECHNICAL REPORTING REQUIREMENTS

Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work (Attachment 1), Delivery Schedule (Attachment 2), and Reporting Requirements (Attachment 3), attached hereto and made a part of this Task Order.

ARTICLE C.2. REPORTING REQUIREMENTS

All reports required herein shall be submitted in electronic format. All electronic contract deliverables shall be submitted via eRDS, available at the following website: <https://erds.niaid.nih.gov/>.

All electronic reports submitted shall be compliant with Section 508 of the Rehabilitation Act of 1973.

Additional information about testing documents for Section 508 compliance, including guidance and specific checklists, by application, can be found at: <http://www.hhs.gov/web/508/index.html> under "Making Files Accessible."

SECTION D – PACKAGING, MARKING AND SHIPPING

No additional requirements beyond those of the base contract.

SECTION E – INSPECTION AND ACCEPTANCE

No additional requirements beyond those of the base contract.

SECTION F – DELIVERIES OR PERFORMANCE

ARTICLE F.1. TASK ORDER COMPLETION PERIOD

- a. The completion date of this task order shall be January 15, 2022.

SECTION G – CONTRACT ADMINISTRATION DATA

ARTICLE G.1. CONTRACTING OFFICER REPRESENTATIVE (COR)

The following COR will represent the Government for the purpose of this Task Order:

Primary COR:

Redacted by agreement

The COR is responsible for: (1) monitoring the Contractor's technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; (2) interpreting the Statement of Work and any other technical performance requirements; (3) performing technical evaluation as required; (4) performing technical inspections and acceptances required by this task order; (5) assisting in the resolution of technical problems encountered during performance.

The Contracting Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) direct or negotiate any changes in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor for any costs incurred during the performance of this contract; (5) otherwise change any terms and conditions of this contract; or (6) sign written licensing agreements. The Government may unilaterally change its COR designation.

ARTICLE G.2. KEY PERSONNEL

The key personnel specified in this contract are considered to be essential to work performance. At least 30 days prior to the contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement's skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the contractor is terminated for cause or separates from the contractor voluntarily with less than 30 days notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.

The following individual is considered to be essential to the work being performed hereunder:

NAME	Role
Redacted by agreement	Principal Investigator (PI)
	Co-Principal Investigator (Co-PI)

SECTION H – SPECIAL CONTRACT REQUIREMENTS

ARTICLE H.1 CARE OF LIVE VERTEBRATE ANIMALS, HHSAR 352.270-5(b) (December 2015)

- a. Before undertaking performance of any contract involving animal-related activities where the species is regulated by the United States Department of Agriculture (USDA), the Contractor shall register with the Secretary of Agriculture of the United States in accordance with 7 U.S.C. 2136 and 9 CFR 2.25 through 2.28. The Contractor shall furnish evidence of the registration to the Contracting Officer.
- b. The Contractor shall acquire vertebrate animals used in research from a dealer licensed by the Secretary of Agriculture under 7 U.S.C. 2133 and 9 CFR 2.1 2.11, or from a source that is exempt from licensing under those sections.
- c. The Contractor agrees that the care, use, and intended use of any live vertebrate animals in the performance of this contract shall conform with the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals (PHS Policy), the current Animal Welfare Assurance (Assurance), the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC) and the pertinent laws and regulations of the United States Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CFR subchapter A, Parts 1-4). In case of conflict between standards, the more stringent standard shall govern.
- d. If at any time during performance of this contract, the Contracting Officer determines, in consultation with the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health (NIH), that the Contractor is not in compliance with any of the requirements and standards stated in paragraphs (a) through (c) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under

this contract until the Contractor corrects the noncompliance. Notice of the suspension may be communicated by telephone and confirmed in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer's written notice of suspension, the Contracting Officer may, in consultation with OLAW, NIH, terminate this contract in whole or in part, and the Contractor's name may be removed from the list of those contractors with Animal Welfare Assurances.

Note : The Contractor may request registration of its facility and a current listing of licensed dealers from the Regional Office of the Animal and Plant Health Inspection Service (APHIS), USDA, for the region in which its research facility is located. The location of the appropriate APHIS Regional Office, as well as information concerning this program may be obtained by contacting the Animal Care Staff, USDA/APHIS, 4700 River Road, Riverdale, Maryland 20737 (Email: ace@aphis.usda.gov ; Web site: (<http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/animalwelfare>).

ARTICLE H.2 ANIMAL WELFARE

All research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy). The PHS Policy can be accessed at: <http://grants1.nih.gov/grants/olaw/references/phspol.htm>

In addition, the research involving live vertebrate animals shall be conducted in accordance with the description set forth in the Vertebrate Animal Section (VAS) of the contractor's technical proposal, which is incorporated by reference.

SECTION I – CONTRACT CLAUSES

In addition to those clauses contained in Base Contract No. HHSN272201700035I, the following clauses apply to this cost-reimbursement task order contract:

ARTICLE I.1. GENERAL CLAUSES FOR A COST-REIMBURSEMENT CONTRACT WITH EDUCATIONAL INSTITUTIONS

This contract incorporates the following clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically as follows: FAR Clauses at: <http://www.acquisition.gov/far/> . HHSAR Clauses at: <http://www.hhs.gov/policies/hhsar/subpart352.html> .

a. FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

<u>FAR</u>	<u>DATE</u>	<u>TITLE</u>
<u>CLAUSE NO.</u>		
52.202-1	Nov 2013	Definitions (Over the Simplified Acquisition Threshold)
52.203-3	Apr 1984	Gratuities (Over the Simplified Acquisition Threshold)
52.203-5	May 2014	Covenant Against Contingent Fees (Over the Simplified Acquisition Threshold)
52.203-6	Sep 2006	Restrictions on Subcontractor Sales to the Government (Over the Simplified Acquisition Threshold)
52.203-7	May 2014	Anti-Kickback Procedures (Over the Simplified Acquisition Threshold)
52.203-8	May 2014	Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity (Over the Simplified Acquisition Threshold)
52.203-10	May 2014	Price or Fee Adjustment for Illegal or Improper Activity (Over the Simplified Acquisition Threshold)
52.203-12	Oct 2010	Limitation on Payments to Influence Certain Federal Transactions (Over \$150,000)

<u>FAR</u>	<u>DATE</u>	<u>TITLE</u>
<u>CLAUSE NO.</u>		
52.203-17	Apr 2014	Contractor Employee Whistleblower Rights and Requirements to Inform Employees of Whistleblower Rights (Over the Simplified Acquisition Threshold)
52.203-99	Feb 2015	Prohibition on Contracting with Entities That Require Certain Internal Confidentiality Agreements (DEVIATION)
52.204-4	May 2011	Printed or Copied Double-Sided on Postconsumer Fiber Content Paper(Over the Simplified Acquisition Threshold)
52.204-10	Oct 2016	Reporting Executive Compensation and First-Tier Subcontract Awards (\$30,000 or more)
52.204-13	Oct 2016	System for Award Management Maintenance
52.209-6	Oct 2015	Protecting the Government's Interest When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment (Over \$35,000)
52.215-2	Oct 2010	Audit and Records - Negotiation [Note: Applies to ALL contracts funded in whole or in part with Recovery Act funds, regardless of dollar value, AND contracts over the Simplified Acquisition Threshold funded exclusively with non-Recovery Act funds.], Alternate II (Aug 2016)
52.215-8	Oct 1997	Order of Precedence - Uniform Contract Format
52.215-10	Aug 2011	Price Reduction for Defective Certified Cost or Pricing Data (Over \$750,000)
52.215-12	Oct 2010	Subcontractor Cost or Pricing Data (Over \$750,000)
52.215-14	Oct 2010	Integrity of Unit Prices (Over the Simplified Acquisition Threshold)
52.215-15	Oct 2010	Pension Adjustments and Asset Reversions (Over \$750,000)
52.215-18	Jul 2005	Reversion or Adjustment of Plans for Post-Retirement Benefits (PRB) other than Pensions
52.215-19	Oct 1997	Notification of Ownership Changes
52.215-21	Oct 2010	Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data - Modifications
52.215-23	Oct 2009	Limitations on Pass-Through Charges (Over the Simplified Acquisition Threshold)
52.216-7	Jun 2013	Allowable Cost and Payment, Alternate II (Aug 2012)
52.216-11	Apr 1984	Cost Contract - No Fee
52.219-8	Nov 2016	Utilization of Small Business Concerns (Over the Simplified Acquisition Threshold)
52.219-9	Jan 2017	Small Business Subcontracting Plan (Over \$700,000, \$1.5 million for Construction)
52.219-16	Jan 1999	Liquidated Damages - Subcontracting Plan (Over \$700,000, \$1.5 million for Construction)
52.222-2	Jul 1990	Payment for Overtime Premium (Over the Simplified Acquisition Threshold) (Note: The dollar amount in paragraph (a) of this clause is \$0 unless otherwise specified in the contract.)
52.222-3	Jun 2003	Convict Labor
52.222-21	Apr 2015	Prohibition of Segregated Facilities
52.222-26	Sep 2016	Equal Opportunity
52.222-35	Oct 2015	Equal Opportunity for Veterans (\$150,000 or more)
52.222-36	Jul 2014	Equal Opportunity for Workers with Disabilities
52.222-37	Feb 2016	Employment Reports on Veterans (\$150,000 or more)
52.222-40	Dec 2010	Notification of Employee Rights Under the National Labor Relations Act (Over the Simplified Acquisition Threshold)
52.222-50	Mar 2015	Combating Trafficking in Persons

<u>FAR</u>	<u>DATE</u>	<u>TITLE</u>
<u>CLAUSE NO.</u>		
52.222-54	Oct 2015	Employment Eligibility Verification (Over the Simplified Acquisition Threshold)
52.223-6	May 2001	Drug-Free Workplace
52.223-18	Aug 2011	Encouraging Contractor Policies to Ban Text Messaging While Driving
52.225-1	May 2014	Buy American - Supplies
52.225-13	Jun 2008	Restrictions on Certain Foreign Purchases
52.227-1	Dec 2007	Authorization and Consent, Alternate I (Apr 1984)
52.227-2	Dec 2007	Notice and Assistance Regarding Patent and Copyright Infringement
52.227-11	May 2014	Patent Rights - Ownership by the Contractor (Note: In accordance with FAR 27.303(b)(2), paragraph (e) is modified to include the requirements in FAR 27.303(b)(2)(i) through (iv). The frequency of reporting in (i) is annual.
52.227-14	Dec 2007	Rights in Data - General, Alternate IV (Dec 2007)
52.232-9	Apr 1984	Limitation on Withholding of Payments
52.232-20	Apr 1984	Limitation of Cost
52.232-23	May 2014	Assignment of Claims
52.232-25	Jul 2013	Prompt Payment, Alternate I (Feb 2002)
52.232-33	Jul 2013	Payment by Electronic Funds Transfer--System for Award Management
52.232-39	Jun 2013	Unenforceability of Unauthorized Obligations
52.233-1	May 2014	Disputes
52.233-3	Aug 1996	Protest After Award, Alternate I (Jun 1985)
52.233-4	Oct 2004	Applicable Law for Breach of Contract Claim
52.242-1	Apr 1984	Notice of Intent to Disallow Costs
52.242-4	Jan 1997	Certification of Final Indirect Costs
52.242-13	Jul 1995	Bankruptcy (Over the Simplified Acquisition Threshold)
52.244-2	Oct 2010	Subcontracts (Over the Simplified Acquisition Threshold), Alternate I (June 2007)
52.244-5	Dec 1996	Competition in Subcontracting (Over the Simplified Acquisition Threshold)
52.244-6	Nov 2017	Subcontracts for Commercial Items
52.245-1	Apr 2012	Government Property, Alternate II (April 2012)
52.245-9	Apr 2012	Use and Charges
52.246-23	Feb 1997	Limitation of Liability (Over the Simplified Acquisition Threshold)
52.249-6	May 2004	Termination (Cost-Reimbursement)
52.249-14	Apr 1984	Excusable Delays
52.253-1	Jan 1991	Computer Generated Forms

b. DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR CHAPTER 3) CLAUSES:

<u>HHSAR</u>	<u>DATE</u>	<u>TITLE</u>
<u>CLAUSE NO.</u>		
352.203-70	Dec 2015	Anti-Lobbying
352.222-70	Dec 2015	Contractor Cooperation in Equal Employment Opportunity Investigations
352.227-70	Dec 2015	Publications and Publicity
352.233-71	Dec 2015	Litigation and Claims
352.237-75	Dec 2015	Key Personnel

[End of GENERAL CLAUSES FOR A NEGOTIATED COST-REIMBURSEMENT CONTRACT W_EDUCATIONAL INSTITUTION- Rev. 11/2017].

ARTICLE I.2. AUTHORIZED SUBSTITUTION OF CLAUSES

No additional clauses beyond those of the base contract.

ARTICLE I.3., ADDITIONAL FAR CONTRACT CLAUSES

This contract incorporates the following clauses by reference, with the same force and effect, as if they were given in full text. Upon request, the Contracting Officer will make their full text available.

1. **HHSAR Clause 352.231-70, Salary Rate Limitation** (December 2015)

Note: *The Salary Rate Limitation is at the Executive Level II Rate.*

See the following website for Executive Schedule rates of pay:

<https://www.opm.gov/policy-data-oversight/pay-leave/salaries-wages/> .

(For current year rates, click on Salaries and Wages/Executive Schedule/Rates of Pay for the Executive Schedule. For prior year rates, click on Salaries and Wages/select Another Year at the top of the page/Executive Schedule/Rates of Pay for the Executive Schedule. Rates are effective January 1 of each calendar year unless otherwise noted.)

ARTICLE I.4., ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT

1. **52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (DEC 2019)**

The Offeror shall not complete the representation in this provision if the Offeror has represented that it “does not provide covered telecommunications equipment or services as a part of its offered products or services to the Government in the performance of any contract, subcontract, or other contractual instrument” in the provision at 52.204-26, Covered Telecommunications Equipment or Services-Representation, or in paragraph (v) of the provision at 52.212-3, Offeror Representations and Certifications-Commercial Items.

(a) *Definitions.* As used in this provision—

“Covered telecommunications equipment or services”, “critical technology”, and “substantial or essential component” have the meanings provided in clause 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment.

(b) *Prohibition.* Section 889(a)(1)(A) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2019, from procuring or obtaining, or extending or renewing a contract to procure or obtain, any equipment, system, or service that uses covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system. Contractors are not prohibited from providing—

(1) A service that connects to the facilities of a third-party, such as backhaul, roaming, or interconnection arrangements; or

(2) Telecommunications equipment that cannot route or redirect user data traffic or permit visibility into any user data or packets that such equipment transmits or otherwise handles.

(c) *Procedures.* The Offeror shall review the list of excluded parties in the System for Award Management (SAM) (<https://www.sam.gov>) for entities excluded from receiving federal awards for “covered telecommunications equipment or services”.

(d) *Representation.* The Offeror represents that it ☐ will, ☐ will not provide covered telecommunications equipment or services to the Government in the performance of any contract, subcontract or other contractual instrument resulting from this solicitation.

(e) *Disclosures.* If the Offeror has represented in paragraph (d) of this provision that it “will” provide covered telecommunications equipment or services”, the Offeror shall provide the following information as part of the offer—

(1) A description of all covered telecommunications equipment and services offered (include brand; model number, such as original equipment manufacturer (OEM) number, manufacturer part number, or wholesaler number; and item description, as applicable);

(2) Explanation of the proposed use of covered telecommunications equipment and services and any factors relevant to determining if such use would be permissible under the prohibition in paragraph (b) of this provision;

(3) For services, the entity providing the covered telecommunications services (include entity name, unique entity identifier, and Commercial and Government Entity (CAGE) code, if known); and

(4) For equipment, the entity that produced the covered telecommunications equipment (include entity name, unique entity identifier, CAGE code, and whether the entity was the OEM or a distributor, if known).

(End of provision)

2. FAR Clause 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (August 2020).

(a) Definitions. As used in this clause—

Covered foreign country means The People’s Republic of China.

Covered telecommunications equipment or services means—

(1) Telecommunications equipment produced by Huawei Technologies Company or ZTE Corporation (or any subsidiary or affiliate of such entities);

(2) For the purpose of public safety, security of Government facilities, physical security surveillance of critical infrastructure, and other national security purposes, video surveillance and telecommunications equipment produced by Hytera Communications Corporation, Hangzhou

Hikvision Digital Technology Company, or Dahua Technology Company (or any subsidiary or affiliate of such entities);

(3) Telecommunications or video surveillance services provided by such entities or using such equipment; or

(4) Telecommunications or video surveillance equipment or services produced or provided by an entity that the Secretary of Defense, in consultation with the Director of National Intelligence or the Director of the Federal Bureau of Investigation, reasonably believes to be an entity owned or controlled by, or otherwise connected to, the government of a covered foreign country.

Critical technology means—

(1) Defense articles or defense services included on the United States Munitions List set forth in the International Traffic in Arms Regulations under subchapter M of chapter I of title 22, Code of Federal Regulations;

(2) Items included on the Commerce Control List set forth in Supplement No. 1 to part 774 of the Export Administration Regulations under subchapter C of chapter VII of title 15, Code of Federal Regulations, and controlled-

(i) Pursuant to multilateral regimes, including for reasons relating to national security, chemical and biological weapons proliferation, nuclear nonproliferation, or missile technology; or

(ii) For reasons relating to regional stability or surreptitious listening;

(3) Specially designed and prepared nuclear equipment, parts and components, materials, software, and technology covered by part 810 of title 10, Code of Federal Regulations (relating to assistance to foreign atomic energy activities);

(4) Nuclear facilities, equipment, and material covered by part 110 of title 10, Code of Federal Regulations (relating to export and import of nuclear equipment and material);

(5) Select agents and toxins covered by part 331 of title 7, Code of Federal Regulations, part 121 of title 9 of such Code, or part 73 of title 42 of such Code; or

(6) Emerging and foundational technologies controlled pursuant to section 1758 of the Export Control Reform Act of 2018 (50 U.S.C. 4817).

Substantial or essential component means any component necessary for the proper function or performance of a piece of equipment, system, or service.

(b) Prohibition. Section 889(a)(1)(A) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2019, from procuring or obtaining, or extending or renewing a contract to procure or obtain, any equipment, system, or service that uses covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system. The Contractor is prohibited from providing to the Government any equipment, system, or service that uses covered telecommunications equipment or services as a substantial or essential component of

any system, or as critical technology as part of any system, unless an exception at paragraph (c) of this clause applies or the covered telecommunication equipment or services are covered by a waiver described in Federal Acquisition Regulation 4.2104.

(c) Exceptions. This clause does not prohibit contractors from providing—

(1) A service that connects to the facilities of a third-party, such as backhaul, roaming, or interconnection arrangements; or

(2) Telecommunications equipment that cannot route or redirect user data traffic or permit visibility into any user data or packets that such equipment transmits or otherwise handles.

(d) Reporting requirement.

(1) In the event the Contractor identifies covered telecommunications equipment or services used as a substantial or essential component of any system, or as critical technology as part of any system, during contract performance, or the Contractor is notified of such by a subcontractor at any tier or by any other source, the Contractor shall report the information in paragraph (d)(2) of this clause to the Contracting Officer, unless elsewhere in this contract are established procedures for reporting the information; in the case of the Department of Defense, the Contractor shall report to the website at <https://dibnet.dod.mil>. For indefinite delivery contracts, the Contractor shall report to the Contracting Officer for the indefinite delivery contract and the Contracting Officer(s) for any affected order or, in the case of the Department of Defense, identify both the indefinite delivery contract and any affected orders in the report provided at <https://dibnet.dod.mil>.

(2) The Contractor shall report the following information pursuant to paragraph (d)(1) of this clause

(i) Within one business day from the date of such identification or notification: the contract number; the order number(s), if applicable; supplier name; supplier unique entity identifier (if known); supplier Commercial and Government Entity (CAGE) code (if known); brand; model number (original equipment manufacturer number, manufacturer part number, or wholesaler number); item description; and any readily available information about mitigation actions undertaken or recommended.

(ii) Within 10 business days of submitting the information in paragraph (d)(2)(i) of this clause: any further available information about mitigation actions undertaken or recommended. In addition, the Contractor shall describe the efforts it undertook to prevent use or submission of covered telecommunications equipment or services, and any additional efforts that will be incorporated to prevent future use or submission of covered telecommunications equipment or services.

(e) Subcontracts. The Contractor shall insert the substance of this clause, including this paragraph (e), in all subcontracts and other contractual instruments, including subcontracts for the acquisition of commercial items.

(End of clause)

2. FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation (Dec 2019).

(a) Definitions. As used in this provision, “covered telecommunications equipment or services” has the meaning provided in the clause 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment.

(b) Procedures. The Offeror shall review the list of excluded parties in the System for Award Management (SAM) (<https://www.sam.gov>) for entities excluded from receiving federal awards for “covered telecommunications equipment or services”.

(c) Representation. The Offeror represents that it ☐ does, ☐ does not provide covered telecommunications equipment or services as a part of its offered products or services to the Government in the performance of any contract, subcontract, or other contractual instrument.

(End of clause)

SECTION J – LIST OF ATTACHMENTS

The following documents are attached and incorporated in this task order:

1. Statement of Work, 3 pages
2. Reporting Requirements, 2 pages
3. Delivery Schedule, 1 page



From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Fri, 6 Aug 2021 14:42:17 +0000
To: [Redacted by agreement] (NIH/NIAID) [E]
Cc: [Redacted by agreement] (NIH/NIAID) [E]
Subject: Re: Contract HHSN272201700035I/75N93020F00003

Thanks for sending. We'll keep an eye out for any additional inquiries and I'll give the communications group within DMID a heads up as well.

From: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>
Date: Friday, August 6, 2021 at 10:37 AM
To: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>
Cc: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@nih.gov>
Subject: FW: Contract HHSN272201700035I/75N93020F00003

FYI, I think you should be aware since you are the COR on the Parent contract. If there is an inquiry this is the Task Order for the beagle experiments. Reading this article it appears that this is more about Dr Fauci than the experiments with beagles. I did a FOI response to the White Coat Project a few months ago. They are an animal rights group that was fishing.

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Friday, August 6, 2021 10:04 AM
To: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@mail.nih.gov>
Cc: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@nih.gov>
Subject: Contract HHSN272201700035I/75N93020F00003

<https://dailycaller.com/2021/08/04/anthony-fauci-niaid-georgia-beagle-experiment/>

We may get a call from the top.

[Redacted by agreement]

Contracting Officer, MID Research Contracts Branch-A
Office of Acquisitions, DEA, NIAID, NIH, DHHS
5601 Fishers Lane
Rockville, Maryland 20852 [Redacted by agreement]
Phone: [Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Fri, 6 Aug 2021 15:55:20 -0400
To: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]
Cc: NIAID BUGS; [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]
Subject: Re: FOR REVIEW: Draft talking points re: LF vaccine grant & contract
Attachments: Lymphatic filariasis contract tps ja_AMO LH.docx, C12_TechProposal_final_9_1_2020.pdf

Dear [Redacted by agreement]

Please find attached the revised document. Also, I'm attaching the technical proposal if you want to take a look.

By the way, I just got threatening calls here too.

Thanks,

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@nih.gov>
Date: Friday, August 6, 2021 at 2:07 PM
To: [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@mail.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement]@nih.gov>
Subject: FOR REVIEW: Draft talking points re: LF vaccine grant & contract

Hi all,

As I mentioned to some of you, my office is getting a few (unpleasant) media and public inquiries/comments related to this story from the Whitecoat Waste Project:

<https://blog.whitecoatwaste.org/2021/07/30/fauci-funding-wasteful-deadly-dog-tests/>.

I'm trying to pull together some basic talking points for Dr. Fauci about the funded research. There isn't much to go on online in terms of the contract with University of GA Research Foundation, so any details you can share with me would be greatly appreciated.

Attached is what I have thus far. Appreciate any input you might have.

Thanks,

[Redacted by agreement]

News and Science Writing Branch

Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room Redacted by agreement
Bethesda, MD 20892

Redacted by

Media line: (301) 402-1663



Page 017 of 111 to Page 052 of 111

Withheld pursuant to exemption

Redacted by agreement
of the Freedom of Information and Privacy Act



From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Mon, 9 Aug 2021 16:38:18 +0000
To: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]
Subject: RE: Filariasis Animal Study

Thanks,

From: [Redacted by agreement] (NIH/NIAID) [E] <[Redacted by agreement]@niaid.nih.gov>
Sent: Monday, August 9, 2021 12:36 PM
To: [Redacted by agreement] (NIH/NIAID) [E] <[Redacted by agreement]@niaid.nih.gov>; [Redacted by agreement] (NIH/NIAID) [E] <[Redacted by agreement]@nih.gov>
Subject: Filariasis Animal Study

FYI

University Defends Vaccine Tests On Dogs After Dr. Fauci And NIH Blasted With Criticism.

Newsweek (8/6, Cole, 2.67M) reported that the White Coat Waste Project, which opposes taxpayer-funded animal testing, criticized the National Institute of Allergy and Infectious Diseases for directing “\$424,455 to the University of Georgia in September 2020 to infect 28 beagles with disease-causing parasites.” White Coat Waste Project research manager Daniel Lopez said that the documents showed NIAID Director Dr. Anthony Fauci “needs to be held accountable for his wasteful and cruel spending.” University of Georgia Associate Vice President for Marketing and Communications Greg Trevor said that the research is for a potential vaccine for the incurable disease and that vaccines must be tested in two animal species before it can be cleared for human clinical trials. He added that “the university followed the humane standards of the Animal Welfare Act, the Public Health Service Policy on Humane Care and Use of Laboratory Animal and the National Research Council Guide for the Care and Use of Laboratory Animals, and other guidelines.”

[Redacted by agreement]

[Redacted by agreement]

Division of Microbiology & Infectious Diseases

[Redacted by agreement] 5601 Fishers Lane

National Institute of Allergy & Infectious Diseases

National Institutes of Health

Bethesda MD 20892 (For FedEx, UPS, and other courier services, use Rockville MD 20852)

Tel.: [Redacted by agreement]

Voice Mail: [Redacted by agreement]

E-mail: [Redacted by agreement]

Assistant: [Redacted by agreement] (T: [Redacted by agreement] E-mail: [Redacted by agreement]@nih.gov)

From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Wed, 25 Aug 2021 11:16:21 -0400
To: [Redacted by agreement] (NIH/NIAID) [E]
Subject: FW: Action: 401643 Perry (University of GA project on lymphatic filariasis)
Attachments: 401643 Perry #2 corr.pdf

Just received this.

From: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov> [Redacted by agreement]
Date: Wednesday, August 25, 2021 at 11:13 AM
To: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>, [Redacted by agreement]
[Redacted by agreement] @nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>
Subject: FW: Action: 401643 Perry (University of GA project on lymphatic filariasis)

Hi all –

Dr. Fauci has received a letter (attached) signed by a number of members of Congress about the University of Georgia lymphatic filariasis project. I need to gather some information from you because I have to draft the response. Please look at the letter and send me some talking points in response to the Congresspersons' questions by noon tomorrow (Thursday). Let me know if you want to have a phone call about this. I really appreciate your help. I hope you are not still getting threatening phone calls about this.

Thanks

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>
Date: Wednesday, August 25, 2021 at 8:30 AM
To: NIAID BUGS <BUGS@niaid.nih.gov>
Cc: NIAID OCGR Correspondence <NIAIDOCGRCorrespondence@mail.nih.gov>, NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>, NIAID DEA DART <dart@mail.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] @niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] @nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] @nih.gov>
Subject: Action: 401643 Perry (University of GA project on lymphatic filariasis)

Hi BUGS -

Attached is correspondence from various members of Congress to Dr. Fauci. They are writing about the University of Georgia Research Foundation project on lymphatic filariasis.

Please prepare a draft reply for Dr. Fauci's signature. The draft will need to undergo NIH OD clearance before it may be signed and sent. We would appreciate your draft by COB Friday, August 27.

Thank you,

Redacted by
agreement



WHITE COAT
WASTE
PROJECT

Congress of the United States
Washington, DC 20515

August 24, 2021

Dr. Anthony Fauci
Director
National Institute of Allergy and Infectious Diseases
5601 Fishers Lane, MSC 9806
Bethesda, Maryland 20892

Dear Dr. Fauci:

We are troubled about reports of expensive, deadly and apparently unnecessary taxpayer-funded experiments on dogs commissioned by NIAID.

According to a recent watchdog report and related media coverage, NIAID spent \$424,455¹ to commission ongoing testing in which over two dozen healthy beagles are to be infected with parasites and then killed to test an experimental vaccine for the tropical human disease lymphatic filariasis.^{2,3} Documents released through the Freedom of Information Act show that the dogs were “vocalizing in pain” during this testing, which is scheduled to run until January 2022.

We are concerned that these NIAID-commissioned tests on dogs are unnecessary and wasteful.

The Food and Drug Administration has stated as recently as last month that, “The FDA does not mandate that human drugs be studied in dogs.”⁴ We also understand that this experimental drug has already been extensively tested in animals, including dogs, primates, gerbils and mice.⁵

In light of the above, please provide the following information by August 30, 2021:

- Are these dog experiments ongoing? Are they still slated to end in January 2022?
- How many dogs have been experimented on and killed to date?
- How much of the \$424,455 has been spent to date on these dog experiments?
- Why did NIAID commission testing on dogs specifically for this experimental human drug when the FDA clearly states that testing on dogs is not required?
- Who at NIAID authorized this dog testing to take place?

Thank you for your attention to this matter.

Sincerely,

¹ https://www.usaspending.gov/award/CONT_AWD_75N93020F00003_7529_HHSN272201700035I_7529

² <https://dailycaller.com/2021/08/04/anthony-fauci-niaid-georgia-beagle-experiment/>

³ <https://www.foxnews.com/media/fauci-report-niaid-109k-research-dogs>

⁴ <https://wjla.com/features/learn-animals-drug-testing-for-rabies-animals>

⁵ <https://www.sbir.gov/node/1915749>



SCOTT PERRY
Member of Congress



BILL POSEY
Member of Congress



DIANA HARSHBARGER
Member of Congress



RODNEY DAVIS
Member of Congress



FRED KELLER
Member of Congress



LOUIE GOHMERT
Member of Congress



W. GREGORY STEUBE
Member of Congress



YVETTE HERRELL
Member of Congress



DANIEL WEBSTER
Member of Congress



BRIAN MAST
Member of Congress



ANDY BIGGS
Member of Congress



KEN CALVERT
Member of Congress



RANDY WEBER
Member of Congress



MADISON CAWTHORN
Member of Congress



GLENN THOMPSON
Member of Congress



From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Wed, 25 Aug 2021 14:22:44 -0400
To: [Redacted by agreement] (NIH/NIAID) [E]
Subject: FW: Action: 401643 Perry (University of GA project on lymphatic filariasis)
Attachments: 401643 Perry #2 corr.pdf

H [Redacted by agreement]

Just an FYI. I received this letter this morning. We are working on a response.

Thanks

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov> [Redacted by agreement]
Date: Wednesday, August 25, 2021 at 11:13 AM
To: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>, [Redacted by agreement] [Redacted by agreement]@nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>
Subject: FW: Action: 401643 Perry (University of GA project on lymphatic filariasis)

Hi all –

Dr. Fauci has received a letter (attached) signed by a number of members of Congress about the University of Georgia lymphatic filariasis project. I need to gather some information from you because I have to draft the response. Please look at the letter and send me some talking points in response to the Congresspersons' questions by noon tomorrow (Thursday). Let me know if you want to have a phone call about this. I really appreciate your help. I hope you are not still getting threatening phone calls about this.

Thanks

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement] niaid.nih.gov>
Date: Wednesday, August 25, 2021 at 8:30 AM
To: NIAID BUGS <BUGS@niaid.nih.gov>
Cc: NIAID OCGR Correspondence <NIAIDOCGRCorrespondence@mail.nih.gov>, NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>, NIAID DEA DART <dart@mail.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@nih.gov>
Subject: Action: 401643 Perry (University of GA project on lymphatic filariasis)

Hi BUGS -

Attached is correspondence from various members of Congress to Dr. Fauci. They are writing about the University of Georgia Research Foundation project on lymphatic filariasis.

Please prepare a draft reply for Dr. Fauci's signature. The draft will need to undergo NIH OD clearance before it may be signed and sent. We would appreciate your draft by COB Friday, August 27.

Thank you,

Redacted by
agreement



Congress of the United States
Washington, DC 20515

August 24, 2021

Dr. Anthony Fauci
Director
National Institute of Allergy and Infectious Diseases
5601 Fishers Lane, MSC 9806
Bethesda, Maryland 20892

Dear Dr. Fauci:

We are troubled about reports of expensive, deadly and apparently unnecessary taxpayer-funded experiments on dogs commissioned by NIAID.

According to a recent watchdog report and related media coverage, NIAID spent \$424,455¹ to commission ongoing testing in which over two dozen healthy beagles are to be infected with parasites and then killed to test an experimental vaccine for the tropical human disease lymphatic filariasis.^{2,3} Documents released through the Freedom of Information Act show that the dogs were “vocalizing in pain” during this testing, which is scheduled to run until January 2022.

We are concerned that these NIAID-commissioned tests on dogs are unnecessary and wasteful.

The Food and Drug Administration has stated as recently as last month that, “The FDA does not mandate that human drugs be studied in dogs.”⁴ We also understand that this experimental drug has already been extensively tested in animals, including dogs, primates, gerbils and mice.⁵

In light of the above, please provide the following information by August 30, 2021:

- Are these dog experiments ongoing? Are they still slated to end in January 2022?
- How many dogs have been experimented on and killed to date?
- How much of the \$424,455 has been spent to date on these dog experiments?
- Why did NIAID commission testing on dogs specifically for this experimental human drug when the FDA clearly states that testing on dogs is not required?
- Who at NIAID authorized this dog testing to take place?

Thank you for your attention to this matter.

Sincerely,

¹ https://www.usaspending.gov/award/CONT_AWD_75N93020F00003_7529_HHSN272201700035I_7529

² <https://dailycaller.com/2021/08/04/anthony-fauci-niaid-georgia-beagle-experiment/>

³ <https://www.foxnews.com/media/fauci-report-niaid-109k-in-research-dogs>

⁴ <https://wjla.com/features/learn-animals-drug-testing-for-rabies-and-male>

⁵ <https://www.sbir.gov/node/1915749>



SCOTT PERRY
Member of Congress



BILL POSEY
Member of Congress



DIANA HARSHBARGER
Member of Congress



RODNEY DAVIS
Member of Congress



FRED KELLER
Member of Congress



LOUIE GOHMERT
Member of Congress



W. GREGORY STEUBE
Member of Congress



YVETTE HERRELL
Member of Congress



DANIEL WEBSTER
Member of Congress



BRIAN MAST
Member of Congress



ANDY BIGGS
Member of Congress



KEN CALVERT
Member of Congress



RANDY WEBER
Member of Congress



MADISON CAWTHORN
Member of Congress



GLENN THOMPSON
Member of Congress



From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Wed, 25 Aug 2021 18:41:30 +0000
To: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]
Subject: Re: Draft for response to congress inquiry
Attachments: Draft Response to 401643 Perry (University of GA project on lymphatic filariasis)-tep.docx

Hi [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement] is better at drafting these than I could ever be, but I hope this helps.

[Redacted by agreement]
[Redacted by agreement]
From: [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement] @nih.gov>
Date: Wednesday, August 25, 2021 at 2:06 PM
To: [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement] @niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement] @niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement] @niaid.nih.gov>
Subject: Re: Draft for response to congress inquiry

Forgot attachment.

From: [Redacted by agreement] @nih.gov>
Date: Wednesday, August 25, 2021 at 2:03 PM
To: [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement] @niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement] @niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement] @niaid.nih.gov>
Subject: Draft for response to congress inquiry

Attached. Please let me know your suggestions and comments. Thanks!

Redacted by agreement

Program Officer
Parasitology and International Program Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane
Rockville, MD 20892-9823



Page 066 of 111

Withheld pursuant to exemption

Redacted by agreement

of the Freedom of Information and Privacy Act



From: [Redacted by agreement]@nih.gov
Sent: Wed, 25 Aug 2021 14:43:12 -0400
To: [Redacted by agreement] (NIH/NIAID) [E]
Subject: Re: Draft for response to congress inquiry

Thank you! That's very helpful. [Redacted by agreement]

On Aug 25, 2021, at 2:41 PM, [Redacted by agreement] (NIH/NIAID) [E]
[Redacted by agreement]@niaid.nih.gov>wrote:

Hi [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement] is better at drafting these than I could ever be, but I hope this helps.

From: [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@nih.gov>
Date: Wednesday, August 25, 2021 at 2:06 PM
To: [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]"
[Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@niaid.nih.gov>
Subject: Re: Draft for response to congress inquiry

Forgot attachment.

From: [Redacted by agreement]@nih.gov>
Date: Wednesday, August 25, 2021 at 2:03 PM
To: [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]"
[Redacted by agreement]@niaid.nih.gov>, [Redacted by agreement] (NIH/NIAID) [E]" [Redacted by agreement]@niaid.nih.gov>
Subject: Draft for response to congress inquiry

Attached. Please let me know your suggestions and comments. Thanks!

Redacted by agreement

Program Officer
Parasitology and International Program Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane
Rockville, MD 20892-9823

<Draft Response to 401643 Perry (University of GA project on lymphatic filariasis)-tep.docx>



From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Thu, 26 Aug 2021 06:54:59 +0000
To: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]
Subject: RE: Draft for response to congress inquiry
Attachments: 1- SOW_LFguard_25Mar2020_Draft B_30Apr20120_AMO_V2-JAtep-JA2tep-JA.docx

Hi [Redacted by agreement]

I fully agree with [Redacted by agreement] about the logical flow to explain why dog study is needed. The original SOW has a very good Background section explaining why the dog study is needed. I attached here for your reference.

[Redacted by agreement]

Hope this helps.

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] @niaid.nih.gov>

Sent: Wednesday, August 25, 2021 2:42 PM

To: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] @nih.gov> [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] @niaid.nih.gov> [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] niaid.nih.gov>

Subject: Re: Draft for response to congress inquiry

Hi [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

is better at drafting these than I could ever be, but I hope this helps.

Redacted by agreement

Redacted by agreement

From: Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @nih.gov>

Date: Wednesday, August 25, 2021 at 2:06 PM

To: Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>, Redacted by agreement (NIH/NIAID) [E]"

Redacted by agreement @niaid.nih.gov>, Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>

Subject: Re: Draft for response to congress inquiry

Forgot attachment.

From: Redacted by agreement @nih.gov>

Date: Wednesday, August 25, 2021 at 2:03 PM

To: Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>, Redacted by agreement (NIH/NIAID) [E]"

Redacted by agreement @niaid.nih.gov>, Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>

Subject: Draft for response to congress inquiry

Attached. Please let me know your suggestions and comments. Thanks!

Redacted by agreement

Program Officer
Parasitology and International Program Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane
Rockville, MD 20892-9823



Page 071 of 111 to Page 073 of 111

Withheld pursuant to exemption

Redacted by agreement
of the Freedom of Information and Privacy Act



From: [Redacted by agreement]@nih.gov
Sent: Thu, 26 Aug 2021 05:50:54 -0400
To: [Redacted by agreement] (NIH/NIAID) [E]
Cc: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]
Subject: Re: Draft for response to congress inquiry

Thank you [Redacted by agreement]

[Redacted by agreement]

[Redacted by agreement]

On Aug 26, 2021, at 2:55 AM, [Redacted by agreement] (NIH/NIAID) [E] <[Redacted by agreement]@niaid.nih.gov> wrote:

Hi [Redacted by agreement]
I fully agree with [Redacted by agreement] about the logical flow to explain why dog study is needed. The original SOW has a very good Background section explaining why the dog study is needed. I attached here for your reference.

[Redacted by agreement]

Hope this helps.

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E] <[Redacted by agreement]@niaid.nih.gov>
Sent: Wednesday, August 25, 2021 2:42 PM
To: [Redacted by agreement] (NIH/NIAID) [E] <[Redacted by agreement]@nih.gov>; [Redacted by agreement] (NIH/NIAID) [E] <[Redacted by agreement]@niaid.nih.gov>; [Redacted by agreement] (NIH/NIAID) [E] <[Redacted by agreement]@niaid.nih.gov>
Subject: Re: Draft for response to congress inquiry

[Redacted by agreement]

Hi [Redacted by agreement]

[Redacted by agreement]

Redacted by agreement

Redacted by agreement is better at drafting these than I could ever be, but I hope this helps.

Redacted by agreement

Redacted by agreement

From: Redacted by agreement (NIH/NIAID) [E] Redacted by agreement @nih.gov>

Date: Wednesday, August 25, 2021 at 2:06 PM

To: Redacted by agreement NIH/NIAID) [E] Redacted by agreement @niaid.nih.gov>, Redacted by agreement (NIH/NIAID) [E]"

Redacted by agreement @niaid.nih.gov> Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>

Subject: Re: Draft for response to congress inquiry

Forgot attachment.

Redacted by agreement

From: Redacted by agreement @nih.gov>

Date: Wednesday, August 25, 2021 at 2:03 PM

To: Redacted by agreement NIH/NIAID) [E] Redacted by agreement @niaid.nih.gov>, Redacted by agreement (NIH/NIAID) [E]"

Redacted by agreement @niaid.nih.gov> Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>

Subject: Draft for response to congress inquiry

Attached. Please let me know your suggestions and comments. Thanks!

Redacted by agreement

Program Officer
Parasitology and International Program Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane
Rockville, MD 20892-9823

From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Thu, 26 Aug 2021 12:14:49 -0400
To: [Redacted by agreement] (NIH/NIAID) [E]
Subject: Canine filarial infection studies

Canine Filarial Infections in a Human *Brugia malayi* Endemic Area of India", *BioMed Research International*, vol. 2014, Article ID 630160, 9 pages, 2014.
<https://www.hindawi.com/journals/bmri/2014/630160/>

The global status of *Dirofilaria immitis* in dogs: a systematic review and meta-analysis based on published articles. *Research in Veterinary Science*
Volume 131, August 2020, Pages 104-116
<https://www.sciencedirect.com/science/article/pii/S0034528819303108?via%3Dihub>

[Redacted by agreement]

Program Officer
Parasitology and International Program Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane
Rockville, MD 20892-9823



From: [Redacted by agreement] (NIH/NIAID) [E]
Sent: Sat, 28 Aug 2021 06:36:50 +0000
To: [Redacted by agreement] (NIH/NIAID) [E]
Cc: [Redacted by agreement] (NIH/NIAID) [E]; [Redacted by agreement] (NIH/NIAID) [E]
Subject: Re: Draft for response to congress inquiry

Sorry, I don't think that i sent anything today. Something being sent? Perhaps I accidentally hit the wrong key? [Redacted by agreement]

Sent from my iPhone

On Aug 27, 2021, at 5:15 PM, [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov> wrote:

[Redacted by agreement]

This looks exactly like the response you sent yesterday. Was that intentional? Or did you intend to send something else?

[Redacted by agreement]

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>
Sent: Friday, August 27, 2021 7:00 PM
To: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>; [Redacted by agreement] (NIH/NIAID) [E]
[Redacted by agreement]@nih.gov>; [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>
Subject: RE: Draft for response to congress inquiry

[Redacted by agreement]

Hi [Redacted by agreement]

[Redacted by agreement]

I fully agree with [Redacted by agreement] about the logical flow to explain why dog study is needed. The original SOW has a very good Background section explaining why the dog study is needed. I attached here for your reference.

[Redacted by agreement]



Hope this helps.

[Redacted by agreement]

From: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov> [Redacted by agreement]
Sent: Wednesday, August 25, 2021 2:42 PM
To: [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@nih.gov>; [Redacted by agreement] (NIH/NIAID) [E]
[Redacted by agreement]@niaid.nih.gov>; [Redacted by agreement] (NIH/NIAID) [E] [Redacted by agreement]@niaid.nih.gov>
Subject: Re: Draft for response to congress inquiry

[Redacted by agreement]

Hi [Redacted by agreement]

Redacted by agreement

Redacted by agreement is better at drafting these than I could ever be, but I hope this helps.

Redacted by agreement

From: Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @nih.gov>

Date: Wednesday, August 25, 2021 at 2:06 PM

To: Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>, Redacted by agreement NIH/NIAID) [E]"

Redacted by agreement @niaid.nih.gov>, Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>

Subject: Re: Draft for response to congress inquiry

Forgot attachment.

From: Redacted by agreement @nih.gov>

Date: Wednesday, August 25, 2021 at 2:03 PM

To: Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>, Redacted by agreement NIH/NIAID) [E]"

Redacted by agreement @niaid.nih.gov>, Redacted by agreement (NIH/NIAID) [E]" Redacted by agreement @niaid.nih.gov>

Subject: Draft for response to congress inquiry

Attached. Please let me know your suggestions and comments. Thanks!

Redacted by agreement

Program Officer
Parasitology and International Program Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane
Rockville, MD 20892-9823

From: Redacted by agreement (NIH/NIAID) [E]
To: Redacted by agreement @uga.edu
Cc: Redacted by agreement
Subject: assurances
Date: Wednesday, February 10, 2021 2:16:00 PM

Following up our call please confirm the following

- Please forward the pertinent info to my office concerning IACUC certificate.
- Your registration with the Department of Agriculture
- Your OLAW number.

Redacted by agreement

Contracting Officer, MID Research Contracts Branch-A
Office of Acquisitions, DEA, NIAID, NIH, DHHS
5601 Fishers Lane
Rockville, Maryland 20852 MSC 9821
Phone: Redacted by agreement



Redacted by agreement

Redacted by agreement

From: Redacted by agreement
To: Invoicing; (NIH/NIAID) [E] (NIH/NIAID) [E]
Cc: Redacted by agreement
Subject: HHSN272201700035I/75N93020F00003/C12 - A0028612RF
Date: Friday, August 27, 2021 1:56:55 PM
Attachments: [image001.png](#)
[image002.jpg](#)
[Invoice A0030460RF.pdf](#)

Good Afternoon,

Please find the attached July 2021 invoice for the above mentioned contract. Feel free to contact me with questions or if you need assistance with anything.

Thanks,

UGA Reference: RNIHX0001258101

Redacted by agreement

Sponsored Projects Administration | *Grants Accounting Specialist I*

310 East Campus Road | Tucker Hall, Redacted by Athens, GA 30602

Redacted by agreement @uga.edu | spa.uga.edu

University of Georgia



Our mission is to be the nation's premier sponsored projects administration team. We are committed to innovative thinking, timely communication, and exceptional service to provide faculty and staff with the highest levels of support as they compete for and manage extramural funding.



CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information or otherwise protected by law. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.



Obtained via FOIA by White Coat Waste Project

UNIVERSITY OF
GEORGIA



We ask for your valuable feedback

ORIGINAL

INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORT

National Institutes of Health National Institute of Allergy and Infectious Diseases DEA, Office of Acquisitions 5601 Fishers Lane Room 3D47, MSC 9821 Rockville, MD 20852				Invoice/Financing Request No.: A0030460RF Date Invoice Prepared: 8/27/2021 Contract No. and Order No. HHSN272201700035I/75N93020F00003/C12 Contract Title: Pre-Clinical Models of Infectious Diseases Effective Date: September 14, 2020 Total Estimated Cost of Contract/Order: \$ 424,455.00			
University of Georgia Research Foundation Post Award Accounting 310 E. Campus Road Athens, Ga. 30602				Total Fixed Fee: Two-Way Match: X Three-Way Match:			
Contact Person: [Redacted by agreement] Grants Accounting Specialist II [Redacted by agreement] @uga.edu				Office of Acquisitions: National Institute of Allergy and Infectious Diseases			
Tel: [Redacted by agreement]				Central Point of Distribution: NIAIDOAInvoices			
DUNS: 00-431-5578 TIN: 58-1353149				Central Point of Distribution: NIAIDOAInvoices			
This invoice/financing request represents reimbursable costs for the period from: 7/1/2021-7/31/2021							
Task C09		Cumulative Percentage of Effort/Hrs		Amount Billed			
		Negotiated	Actual	Current	Cumulative	Cost at Completion	Contract Value
Expenditure Category							Variance
Direct Costs:							
Direct Labor		Labor Hours		Labor Costs			
Fringe Benefits __%							
Accountable Property				Itemized Cost			
Materials & Supplies							
Premium Pay							
Consultant Fees							
Travel							
Subcontracts							
Other							
Total Direct Costs							
Cost of Money __%							
Indirect Costs 51%							
Fixed Fee __%							
Total Amount Claimed							
Grand Totals							
"I hereby certify that all payments requested are for appropriate purposes and in accordance with the contract."							
Personal Info: [Redacted by agreement]				Grants Accounting Specialist II			
[Redacted by agreement]				Title			
*Attach details as specified in the contract or requested by the Contracting Officer							

Business Unit	Project	Activity	Dept	Account	Transaction Description	Acctg Date	Trans Date	Supplier/Vendor ID	Supplier/Vendor Name	PO No.	PO UGAMart	Voucher #	Journal ID	Journal Date	Transaction Amount
18400	RNIHX0001258101	A00	34006250	511100	Salaries-Regular Faculty	7/30/2021	7/30/2021						P000184945	7/30/2021	Labor Costs
18400	RNIHX0001258101	A00	34006250	522100	Salaries-Staff	7/2/2021	7/2/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	522100	Salaries-Staff	7/16/2021	7/16/2021						P000183013	7/16/2021	
18400	RNIHX0001258101	A00	34006250	522100	Salaries-Staff	7/30/2021	7/30/2021						P000185206	7/30/2021	
18400	RNIHX0001258101	A00	34006250	522200	Additional Straight Time	7/16/2021	7/16/2021						P000183013	7/16/2021	
18400	RNIHX0001258101	A00	34006250	522200	Additional Straight Time	7/30/2021	7/30/2021						P000185206	7/30/2021	
Salary															Itemized Cost
18400	RNIHX0001258101	A00	34006250	551100	FICA-Employer OASDI	7/2/2021	7/2/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	551100	FICA-Employer OASDI	7/16/2021	7/16/2021						P000183013	7/16/2021	
18400	RNIHX0001258101	A00	34006250	551100	FICA-Employer OASDI	7/30/2021	7/30/2021						P000184945	7/30/2021	
18400	RNIHX0001258101	A00	34006250	551100	FICA-Employer OASDI	7/30/2021	7/30/2021						P000185206	7/30/2021	
18400	RNIHX0001258101	A00	34006250	551200	FICA-Employer Medicare	7/2/2021	7/2/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	551200	FICA-Employer Medicare	7/16/2021	7/16/2021						P000183013	7/16/2021	
18400	RNIHX0001258101	A00	34006250	551200	FICA-Employer Medicare	7/30/2021	7/30/2021						P000184945	7/30/2021	
18400	RNIHX0001258101	A00	34006250	551200	FICA-Employer Medicare	7/30/2021	7/30/2021						P000185206	7/30/2021	
18400	RNIHX0001258101	A00	34006250	552100	Teachers Retirement System	7/2/2021	7/2/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	552100	Teachers Retirement System	7/16/2021	7/16/2021						P000183013	7/16/2021	
18400	RNIHX0001258101	A00	34006250	552100	Teachers Retirement System	7/30/2021	7/30/2021						P000185206	7/30/2021	
18400	RNIHX0001258101	A00	34006250	552200	Optional Retirement Plans	7/30/2021	7/30/2021						P000184945	7/30/2021	
18400	RNIHX0001258101	A00	34006250	553116	Group Health Ins-Kaiser HMO	7/2/2021	7/2/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	553116	Group Health Ins-Kaiser HMO	7/16/2021	7/16/2021						P000183013	7/16/2021	
18400	RNIHX0001258101	A00	34006250	553123	Group Health Ins-PPO Alt	7/30/2021	7/30/2021						P000184945	7/30/2021	
18400	RNIHX0001258101	A00	34006250	553128	Group Health Ins-HDHP Alt	7/2/2021	7/2/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	553128	Group Health Ins-HDHP Alt	7/16/2021	7/16/2021						P000183013	7/16/2021	
18400	RNIHX0001258101	A00	34006250	553201	Group Life Ins-Basic Life	7/2/2021	7/2/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	553201	Group Life Ins-Basic Life	7/16/2021	7/16/2021						P000183013	7/16/2021	
18400	RNIHX0001258101	A00	34006250	553201	Group Life Ins-Basic Life	7/30/2021	7/30/2021						P000184945	7/30/2021	
Benefits															
18400	RNIHX0001258101	A00	34006250	727115	Tests and Analysis	7/14/2021	7/14/2021						1000182642	7/14/2021	
18400	RNIHX0001258101	A00	34006250	727116	Veterinary Services	7/20/2021	7/20/2021						1000183759	7/20/2021	
Operating															
18400	RNIHX0001258101	A00	34006250	753120	Contracts-Grant Sub up to \$25K	7/7/2021	5/11/2021	VN0011219	Subcontractor Info			10678511	APACC81863	7/7/2021	
18400	RNIHX0001258101	A00	34006250	753120	Contracts-Grant Sub up to \$25K	7/7/2021	6/9/2021	VN0011219				10678489	APACC81863	7/7/2021	
Subs															
Total Direct															
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021	VN0011219	Subcontractor Info			10678489	APACC81863	7/7/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021	VN0011219				10678511	APACC81863	7/7/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						1000182642	7/14/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						1000183759	7/20/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021						P000181377	7/2/2021	
18400	RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	7/3									

18400	RNIHX0001258101 A00	34006250 951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021
18400	RNIHX0001258101 A00	34006250 951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021
18400	RNIHX0001258101 A00	34006250 951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021
18400	RNIHX0001258101 A00	34006250 951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021
18400	RNIHX0001258101 A00	34006250 951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021
18400	RNIHX0001258101 A00	34006250 951100	Allocated OH-Spons Agreements	7/31/2021	8/6/2021

P000184945	7/30/2021
P000185206	7/30/2021
P000185206	7/30/2021
P000185206	7/30/2021
P000185206	7/30/2021
P000185206	7/30/2021

Itemized Cost

Indirect

Total Expenses



Obtained via FOIA by White Coat Waste Project

PAYROLL SUMMARY

	Salary	Benefits	Total
Personnel	Labor Costs		
TOTAL	\$		

Employee Name	Position	Fund	Dept	Project	Activity	Account	Pay End Date	Expended Amount	Acctg Date
Personnel	40012774	20000	34006250	RNIHX0001258101	A00	522100	6/26/2021	Labor Costs	7/2/2021
	40012774	20000	34006250	RNIHX0001258101	A00	522100	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	522100	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	522100	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	522100	7/24/2021		7/30/2021
	40012774	20000	34006250	RNIHX0001258101	A00	522200	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	551100	6/26/2021		7/2/2021
	40012774	20000	34006250	RNIHX0001258101	A00	551100	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	551100	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	551100	7/24/2021		7/30/2021
	40012774	20000	34006250	RNIHX0001258101	A00	551200	6/26/2021		7/2/2021
	40012774	20000	34006250	RNIHX0001258101	A00	551200	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	551200	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	551200	7/24/2021		7/30/2021
	40012774	20000	34006250	RNIHX0001258101	A00	552100	6/26/2021		7/2/2021
	40012774	20000	34006250	RNIHX0001258101	A00	552100	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	552100	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	552100	7/24/2021		7/30/2021
	40012774	20000	34006250	RNIHX0001258101	A00	553201	6/26/2021		7/2/2021
	40012774	20000	34006250	RNIHX0001258101	A00	553201	7/10/2021		7/16/2021
	40012774	20000	34006250	RNIHX0001258101	A00	553201	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	522100	6/26/2021		7/2/2021
	11902332	20000	34006250	RNIHX0001258101	A00	522100	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	522100	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	522100	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	522100	7/24/2021		7/30/2021
	11902332	20000	34006250	RNIHX0001258101	A00	551100	6/26/2021		7/2/2021
	11902332	20000	34006250	RNIHX0001258101	A00	551100	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	551100	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	551100	7/24/2021		7/30/2021
	11902332	20000	34006250	RNIHX0001258101	A00	551200	6/26/2021		7/2/2021
	11902332	20000	34006250	RNIHX0001258101	A00	551200	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	551200	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	551200	7/24/2021		7/30/2021
	11902332	20000	34006250	RNIHX0001258101	A00	552100	6/26/2021		7/2/2021
	11902332	20000	34006250	RNIHX0001258101	A00	552100	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	552100	7/10/2021		7/16/2021
	11902332	20000	34006250	RNIHX0001258101	A00	552100	7/24/2021		7/30/2021

Obtained via FOIA by White Coat Waste Project

Personnel

21008658	20000	34006250	RNIHX0001258101 A00	552100	6/26/2021
21008658	20000	34006250	RNIHX0001258101 A00	552100	7/10/2021
21008658	20000	34006250	RNIHX0001258101 A00	552100	7/10/2021
21008658	20000	34006250	RNIHX0001258101 A00	552100	7/24/2021
21008658	20000	34006250	RNIHX0001258101 A00	553201	6/26/2021
21008658	20000	34006250	RNIHX0001258101 A00	553201	7/10/2021
21008658	20000	34006250	RNIHX0001258101 A00	553201	7/10/2021

Labor Costs	7/2/2021
	7/16/2021
	7/16/2021
	7/30/2021
	7/2/2021
	7/16/2021
	7/16/2021





THE UNIVERSITY OF GEORGIA®
College of Veterinary Medicine

Department of Pathology
College of Veterinary Medicine
University of Georgia
Athens, GA 30602
Phone: 706-542-5837 Fax: 706-542-5828

Account #:
Direct Charge Account:

Statement Date: July 07, 2021

C12 Dogs

Remit All Payments to:

Previous Balance
\$0.00

Balance Due

Return upper portion with payment. Make check payable to : Clinpath

Statement Date: July 07, 2021

Account #: 812814

Direct Charge Account:

C12 Dogs

Starting Balance \$0.00

Date	Transaction Type	Amount	Balance
07/06/2021	Invoice 459753	<input type="text" value="Itemized Cost"/>	
Ending Balance			

Balance History:	>30 Days \$0.00	>60 Days \$0.00	>90 Days \$0.00	>120 Days \$0.00	>150 Days \$0.00
------------------	--------------------	--------------------	--------------------	---------------------	---------------------

Date: 7/6/2021

Invoice #: 459753

For: Redacted by agreement C12 Dogs

Account #: Proprietary Info

Invoice Summary

DR Redacted by agreement	Itemized Cost
Invoice Total:	

Invoice Details

Contact/Reference	Received	Finalized	Test Name	Qty	Charge
-------------------	----------	-----------	-----------	-----	--------

RDVM: DR Redacted by agreement

Accession #: R21-014235 06/23/2021 06/24/2021

Clinic: UGA Veterinary Teaching Hospital

Patient: Bon Jovi

Small Animal Profile

14

Itemized Cost

Ozzy

CBC (Small Animal)

14

Lynyrd

Accession Total :

Garth

George

Vince

Travis

Bach

Beethoven

Mozart

Eminem

Jay-Z

Ice Cube

Snoop Dogg

RDVM: DR Redacted by agreement	Subtotal	Itemized Cost
---	----------	---------------

Invoice Total:

Itemized Cost



University Research
Animal Resources
University of Georgia
706-542-5884

PER DIEM CHARGE STATEMENT

MONTH BILLED June 20-30 2021

INVESTIGATOR

Redacted by agreement

Business Manager:

Redacted by agreement

DEPARTMENT INFECTIOUS DISEASE

SPEEDTYPE

PROJECT ID RNIHX0001258101

A00

CHART STRING FUND

20000

PROGRAM

12100

CLASS

61018

DEPT

34006250

THE TOTAL BILLED WILL BE AUTOMATICALLY DEBITED FROM THE ACCOUNT LISTED ABOVE
THROUGH AN INTRA-UNIVERSITY CHARGE FORM. THIS FORM IS FOR YOUR RECORDS.

PER DIEM CHARGES

DAYS	SPECIES	CAGE TYPE	FACILITY	ROOM	RATE	COST
154	Dog	Run Group	ICF	Specific Animal Location	Itemized Cost	
0	Dog	Run Single	ICF			
0	Cat	Group	VBF			
					SUBTOTAL	Itemized Cost
					OTHER CHARGES	
					TOTAL BILLED	

OTHER CHARGES

DATE	SERVICE	COST

Subcontractor Info

INVOICE

Originating Office:

Subcontractor Info

Bill to:

University of Georgia
Sponsored Projects Administrat
310 E Campus Rd

Athens, GA 30602

Sponsor Agreement #: UofG HHSN272201700035I

Subcontractor Info

Long Description:

Lymphatic Filariasis Vaccine LFguard Efficacy Trial in Dogs

Make Check Payable to:

Subcontractor Info

Remit to:

Subcontractor Info

Subcontractor Info

Date: 11-May-21

Ref #: EA606

Invoice #: 001 - 000 - EA606

Period: 14-Sep-20 - 30-Apr-21

Subcontractor Info

Expense Group

Budget

Previous Billings

This Billing

Total Billings

Budget Pool
Salaries & Wages
Fringe Benefits
Services

Itemized Cost

.00
.00
.00
.00

Labor Costs

.00 .00

Total Direct Costs
F&A Costs

Itemized Cost

F & A

Total
Less Previous Vouchers
Total Billing

Itemized Cost

Accounts Receivable Balance
Cash Collected

Itemized Cost
.00

Includes This Billing

By signing this report, I certify to the best of my knowledge and belief that the report is true, complete, and accurate, and the expenditures, disbursements and cash receipts are for the purposes and objectives set forth in the terms and conditions of the Federal award. I am aware that any false, fictitious, or fraudulent information, or the omission of any material fact, may subject me to criminal, civil or administrative penalties for fraud, false statements, or false claims, (U.S. Code Title 18, Section 1001 and Title 31, Sections 3729-3730 and 3801-3812).

Redacted by agreement; Personal Signature

Redacted by agreement

Director, Office of Sponsored Programs

To insure proper credit, return one (1) copy of invoice with remittance or include UI ref # and invoice # on payment. Billing inquiries may be directed to: gcopost@uic.edu or (312) 996-5961.

Obtained via FOIA by White Coat Waste Project

Subcontractor Info

INVOICE

Originating Office:

Subcontractor Info

Bill to:

University of Georgia
Sponsored Projects Administrat
310 E Campus Rd

Athens, GA 30602

Sponsor Agreement #: UofG HHSN2722017000351

Long Description:

Lymphatic Filariasis Vaccine LFguard Efficacy Trial in Dogs

Make Check Payable to:

Subcontractor Info

Remit to:

Subcontractor Info

Subcontractor
Info

Date: 09-Jun-21

Ref #: EA606

Invoice #: 002 - 000 - EA606

Period: 01-May-21 - 31-May-21

Subcontractor Info

Expense Group

Budget

Previous Billings

This Billing

Total Billings

Budget Pool

Itemized Cost

.00

.00

.00

Salaries & Wages

.00

Fringe Benefits

.00

Materials & Supplies

.00

Services

.00

Labor Costs

Itemized Cost

Total Direct Costs
F&A Costs

Itemized Cost
F & A

Total

Less Previous Vouchers

Total Billing

Itemized Cost

Accounts Receivable Balance
Cash Collected

Itemized Cost

.00

Includes This Billing

By signing this report, I certify to the best of my knowledge and belief that the report is true, complete, and accurate, and the expenditures, disbursements and cash receipts are for the purposes and objectives set forth in the terms and conditions of the Federal award. I am aware that any false, fictitious, or fraudulent information, or the omission of any material fact, may subject me to criminal, civil or administrative penalties for fraud, false statements, false claims or otherwise. (U.S. Code Title 18, Section 1001 and Title 31, Sections 3729-3730 and 3801-3812).

Redacted by agreement; Personal Signature

Redacted by agreement

Director, Office of Sponsored Programs

To insure proper credit, return one (1) copy of invoice with remittance or include UI ref # and invoice # on payment. Billing inquiries may be directed to: gcopost@uic.edu or (312) 996-5961.

Obtained via FOIA by White Coat Waste Project

Redacted by agreement

From:

Redacted by agreement

To:

Redacted by agreement; NIH/NIAID) [E]; NIAID OA Invoices; Redacted by agreement; NIH/NIAID) [E]

Cc:

Redacted by agreement

Subject:

HHSN272201700035I/75N93020F00003/C12- A0024182RF

Date:

Wednesday, February 17, 2021 8:32:26 AM

Attachments:

[image005.png](#)

[image006.png](#)

[HHSN272201700035I-75N93020F00003-C12-Dec-2020.pdf](#)

Good Morning,

Please find the attached December 2020 invoice for the above mentioned contract. Feel free to contact me with questions or if you need assistance with anything.

Hope you have a great day!

Regards,

Redacted by agreement

UGA Reference: RNIHX0001258101

Redacted by agreement

Sponsored Projects Administration | *Grants Accounting Specialist II*

310 East Campus Rd | Tucker Hall | Athens, GA 30602

Redacted by agreement

[uga.edu](#)

University of Georgia



Our mission is to be the nation's premier sponsored projects administration team. We are committed to innovative thinking, timely communication, and exceptional service to provide faculty and staff with the highest levels of support as they compete for and manage extramural funding.





Obtained via FOIA by White Coat Waste Project

UNIVERSITY OF
GEORGIA

Tell Us How We Are Doing!



ORIGINAL

INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORT

National Institutes of Health
National Institute of Allergy and Infectious Diseases
DEA, Office of Acquisitions
5601 Fishers Lane
Room 3D47, MSC 9821
Rockville, MD 20852

University of Georgia Research Foundation
Post Award Accounting
310 E. Campus Road
Athens, Ga. 30602

Contact Person: [Redacted by agreement]

Grants Accounting Specialist II

[Redacted by agreement] @uga.edu

[Redacted by agreement]

DUNS: 00-431-5578

TIN: 58-1353149

Invoice/Financing Request No.:

A0024182RF

Date Invoice Prepared: 2/17/2021

Contract No. and Order No.

HHSN272201700035I/75N93020F00003/C12

Contract Title: Pre-Clinical Models of Infectious Diseases

Effective Date: September 14, 2020

Total Estimated Cost of Contract/Order:

\$ 424,455.00

Total Fixed Fee:

Two-Way Match: X

Three-Way Match:

Office of Acquisitions:

National Institute of Allergy and Infectious Diseases

Central Point of Distribution: NIAIDOAInvoices

This invoice/financing request represents reimbursable costs for the period from:

12/1/2020-12/31/2020

Task CO9	Cumulative Percentage of Effort/Hrs		Amount Billed		Cost at Completion	Contract Value	Variance
	Negotiated	Actual	Current	Cumulative			
Expenditure Category							
Direct Costs:							
Direct Labor	Labor Hours		Labor Costs				
Fringe Benefits __%							
Accountable Property			Itemized Cost				
Materials & Supplies							
Premium Pay							
Consultant Fees							
Travel							
Subcontracts							
Other							
Total Direct Costs							
Cost of Money __%							
Indirect Costs 51%							
Fixed Fee __%							
Total Amount Claimed							
Grand Totals							

"I hereby certify that all payments requested are for appropriate purposes and in accordance with the contract."

[Redacted by agreement; Personal Signature]

Name

Grants Accounting Specialist II

Title

*Attach details as specified in the contract or requested by the Contracting Officer

EXPENSES: 12/1/2020-12/31/2020

Project	Activity	Dept	Account	Transaction Description	Acctg Date	Trans Date	Journal ID	Journal Date	Transaction Amount
RNIHX0001258101	A00	34006250	727115	Tests and Analysis	12/2/2020	12/2/2020	1000149829	12/2/2020	Itemized Cost
								OPERATING	
								\$	
RNIHX0001258101	A00	34006250	951100	Allocated OH-Spons Agreements	12/31/2020	1/9/2021	1000149829	12/2/2020	
								IDC	
								\$	
								TOTAL	
								\$	



Obtained via FOIA by White Coat Waste Project



THE UNIVERSITY OF GEORGIA®
College of Veterinary Medicine

Department of Pathology
College of Veterinary Medicine
University of Georgia

Athens, GA 30602
Phone: 706-542-5837 Fax: 706-542-5828

Account #
Direct Charge Account

Statement Date: December 02, 2020

C12 Dogs RNIHX0001258101
University of Georgia VMC
2200 College Station Rd
Athens, GA 30602

Remit All Payments to:

Previous Balance
\$0.00

Balance Due

Return upper portion with payment. Make check payable to : Clinpath

Statement Date: December 02, 2020

Account # Direct Charge Account
C12 Dogs RNIHX0001258101

Starting Balance			\$0.00
Date	Transaction Type	Amount	Balance
12/01/2020	Invoice 448933	<input type="text" value="Itemized Cost"/>	
Ending Balance			

Balance History:	>30 Days	>60 Days	>90 Days	>120 Days	>150 Days
	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00



Date: 12/1/2020

Invoice #: 448933

Account #: Proprietary Info

For: C12 Dogs RNIHX0001258101
University of Georgia VMC
2200 College Station Rd
Athens, GA 30602

Invoice Summary

DR

Redacted by agreement

Itemized Cost

Invoice Total:

Invoice Details

Contact/Reference	Received	Finalized	Test Name	Qty	Charge
-------------------	----------	-----------	-----------	-----	--------

RDVM: DR

Redacted by agreement

Accession #: R20-022120 11/19/2020 11/24/2020

Clinic: UGA Veterinary Teaching Hospital

Patient: Monica

CBC (Small Animal)

14

Itemized Cost

Phoebe

Small Animal Profile

14

Rachel

Accession Total :

DJ

Kimmie

Stephanie

Michelle

Blossom

Bubbles

Buttercup

Lane

Rory

Sookie

Lorelai

RDVM: DR

Redacted by agreement

Subtotal

Itemized Cost

Invoice Total:

Contract Number: HHSN272201700035I/75N93020F00003 Task: C12 May 2021

Contract Number: HHSN272201700035I

Task Order Number: 75N93020F00003

Task: C12

Title: Lymphatic Filariasis Vaccine (LFguard) Efficacy Trial in Dogs

Period of performance: April 25, 2021 to May 24, 2021

Contractor: University of Georgia
College of Veterinary Medicine
Department of Infectious Diseases
501 D.W. Brooks Drive
Athens, GA 30602

Due Date: May 25, 2021



The following is the report for the reporting period ending May 24, 2021.

Progress for this month is documented in a progress email with the COR, [Redacted by agreement] and under the heading PROGRESS.

I. MONTHLY EMAIL IN LIEU OF A CONFERENCE CALL

COR approved email May 14, 2021.

Hello [Redacted by agreement]

Here is a summary of our progress to date:

1. Dogs arrived at UGA on Nov. 12. The study started on Nov. 19 after the 7-day mandated acclimation period. Physical exams were performed, CBC/chemistry was performed, urine collected, and serum and blood was shipped [Redacted by agreement] (subcontractor). Vaccines were prepared and administered according to instructions provided by the vaccine producer. Animals were allocated in a random-block design.
2. Physical exams have been performed weekly and the three rounds of vaccines administered.
3. No adverse events have been reported.
4. Dogs will be euthanized on June 8.
5. I had a discussion with [Redacted by agreement] in order to get the next round of vaccines, which will occur on June 23rd (dogs arrive June 10).

Please let me know what questions you have, and if you want to have a call Monday.

Thanks and have a good weekend.

[Redacted by agreement]

II. PROGRESS

A. Physical Exams

Physical exams have been performed weekly. All of the dogs' physical exam findings have been within normal limits.

B. Vaccination

All vaccines have been administered. See previous reports.

C. Proprietary Info

All dogs were challenged on February 11, 2021 with Proprietary Info
No adverse events post-challenge were noted. Proprietary Info should be included in next report.

D. **Second phase of study**

During a phone call with the COR on Wednesday April 21, 2021, it was decided the gender of dogs for the next phase will be male. There has been communication about shipping the next round of vaccines/placebos to UGA.



Contract Number: HHSN272201700035I/75N93020F00003 Task: C12 April 2021

Contract Number: HHSN272201700035I

Task Order Number: 75N93020F00003

Task: C12

Title: Lymphatic Filariasis Vaccine (LFguard) Efficacy Trial in Dogs

Period of performance: March 25, 2021 to April 24, 2021

Contractor: University of Georgia
 College of Veterinary Medicine
 Department of Infectious Diseases
 501 D.W. Brooks Drive
 Athens, GA 30602

Due Date: April 25, 2021



The following is the report for the reporting period ending April 24, 2021.

Progress for this month is documented in a progress email with the COR, [Redacted by agreement] and under the heading PROGRESS.

I. CONFERENCE CALL MINUTES

COR approved minutes from call on April 15, 2021. Minutes are below.

The zoom call commenced at 3 PM Eastern on Thursday April 15th.

Key points discussed were:

1. End of first phase of study is June 8th.
2. [Proprietary Info] data will be sent as soon as possible to the COR.
3. We need vaccines before the start on the second phase.
4. The second phase will begin in late June.

II. PROGRESS

A. Physical Exams

Physical exams have been performed weekly. All of the dogs' physical exam findings have been within normal limits.

B. Vaccination

All vaccines have been administered. See previous reports.

C. [Proprietary Info]

All dogs were challenged on February 11, 2021 with [Proprietary Info]
No adverse events post-challenge were noted.

D. Second phase of study

During a phone call with the COR on Wednesday April 21, 2021, it was decided the gender of dogs for the next phase will be male.

Contract Number: HHSN272201700035I/75N93020F00003 Task: C12 June 2021

Contract Number: HHSN272201700035I

Task Order Number: 75N93020F00003

Task: C12

Title: Lymphatic Filariasis Vaccine (LFguard) Efficacy Trial in Dogs

Period of performance: May 25, 2021 to June 24, 2021

Contractor: University of Georgia
 College of Veterinary Medicine
 Department of Infectious Diseases
 501 D.W. Brooks Drive
 Athens, GA 30602

Due Date: June 25, 2021



The following is the report for the reporting period ending June 24, 2021.

Progress for this month is documented under the heading PROGRESS.

I. MONTHLY CONFERENCE CALL

The call commenced at 10 am Eastern on June 15, 2021.

People present:

Personnel

Discussion:

The first phase of the study has been completed.

Proprietary Info

 counts will be provided in the next monthly report.

Dogs from the first round have been euthanized, and dogs for the second round have arrived.

II. PROGRESS

A. First round of experiments

This is now complete.

--

 counts are attached (**Appendix A**).

B. Second round of experiments

Dogs arrived June 10, 2021. Due to supply chain issues, the first round of immunizations that were to occur on June 23, 2021 has been delayed. The COR has been informed. Updates will be provided for the next report.



Proprietary Info



WHITE COAT
WASTE
PROJECT

Contract Number: HHSN272201700035I/75N93020F00003 Task: C12 July 2021

Contract Number: HHSN272201700035I

Task Order Number: 75N93020F00003

Task: C12

Title: Lymphatic Filariasis Vaccine (LFguard) Efficacy Trial in Dogs

Period of performance: June 25, 2021 to July 24, 2021

Contractor: University of Georgia
 College of Veterinary Medicine
 Department of Infectious Diseases
 501 D.W. Brooks Drive
 Athens, GA 30602

Due Date: July 25, 2021



The following is the report for the reporting period ending June 24, 2021.

Progress for this month is documented under the heading PROGRESS.

I. MONTHLY CONFERENCE CALL

The call commenced by ZOOM at 3 PM Eastern on July 14, 2021.

People present:

Personnel

Summary of call:

- [Redacted by agreement] was scheduled to be shipping supplies to [Redacted by agreement] Monday 7/12 [Redacted by agreement] should be sending us [Proprietary Info] 7/14/21 for arrival 7/15/21.
- We want to do immunization 1/3 for the red, white and blue groups Wednesday July 28th. This would put the red, white and blue groups 4 weeks behind the green group who received immunization 1/3 June 30th.
- Assuming we do immunization 1/3 for the red, white and blue groups Wednesday July 30th, we will need funding for an additional 4 weeks of per diems for ALL 14 dogs. This is in addition to the 4 days worth of per diems that we already requested.
 - Although the study will be ending 4 weeks earlier for the green group, due to animal welfare concerns that come down to social housing we would need to keep the green group around until the red, white and blue groups are ready to be euthanized as well.
- [Redacted by agreement] will not need new baseline samples for the red, white and blue groups
- In terms of the challenge:
 - A - If we challenge the groups according to the schedule, the green group would be challenged with a different batch of [Redacted] than the red, white and blue groups due to the 4-week difference
 - B - If we pushed the challenge date for the green group back 4 weeks all of the dogs could be challenged with the same batch of [Redacted] However, this would mean the green group is getting challenged 8 weeks post immunization 3/3 while the red, white and blue groups will be getting challenged 4 weeks post immunization 3/3.

Proprietary Info

Proprietary Info

II. PROGRESS

A. First round of experiments

This is now complete.

B. Second round of experiments

Dogs arrived June 10, 2021. Due to supply chain issues, the first round of immunizations that were to occur was delayed until June 30, 2021. The COR has been informed (see minutes above).

The second immunization of the green group will happen on July 28, 2021. The first immunization of the red, white, and blue group will also happen on July 28, 2021.

